The OCEANUS study, a large-scale real-world analysis published in JAMA Oncology, sheds light on the optimal integration of radiotherapy and immunotherapy in advanced non-small cell lung cancer (NSCLC). The study's findings challenge conventional wisdom and offer valuable insights for clinicians treating this challenging disease.
Sequential Treatment: A Clear Advantage
One of the most striking findings of the OCEANUS study is the apparent superiority of sequential treatment over concurrent administration of radiotherapy and immunotherapy. This finding is supported by observations from the PACIFIC trial, where patients received durvalumab after completion of chemoradiotherapy. In contrast, studies evaluating concurrent immunotherapy during radiotherapy have produced less convincing results.
In the OCEANUS study, patients treated with sequential immunoradiotherapy experienced significantly longer survival compared with those receiving concurrent treatment. This finding suggests that allowing radiotherapy to complete before initiating immune checkpoint inhibition may create a more favorable environment for immune activation and long-term disease control.
Definitive Radiotherapy: A Key Modifier
The survival advantage associated with sequential treatment appeared most pronounced among patients receiving definitive-dose radiotherapy. Definitive radiotherapy is generally used in patients with unresectable locally advanced disease and delivers substantially higher radiation doses than palliative treatment. Such regimens can produce profound effects on both tumor burden and immune-cell populations.
In this subgroup, sequential treatment was associated with a marked improvement in survival. This finding raises the possibility that treatment intent and radiation dose may influence the optimal timing of immunotherapy.
Immunotherapy Maintenance After Radiotherapy
The study also explored the role of immunotherapy maintenance after radiotherapy in refractory disease. Radiotherapy is frequently used in this setting for symptom control, treatment of oligoprogressive lesions, or management of resistant disease sites. Whether immunotherapy should be resumed after radiotherapy remains uncertain.
In the OCEANUS study, patients who restarted immune checkpoint inhibition following radiotherapy demonstrated numerically longer survival than those who did not receive maintenance immunotherapy. Although these differences did not reach statistical significance, the magnitude of improvement suggests that selected patients may derive benefit from continued immune stimulation after local radiation therapy.
The Continuing Role of Chemotherapy
As immunotherapy becomes increasingly dominant in NSCLC management, the value of chemotherapy within combined treatment strategies continues to be debated. The OCEANUS analysis demonstrated that chemotherapy remained associated with improved outcomes in newly diagnosed advanced disease. However, its benefit appeared highly dependent on clinical context.
Among newly diagnosed patients receiving immunoradiotherapy, chemotherapy was associated with longer survival. The advantage was particularly evident in patients treated with concurrent immunoradiotherapy. In contrast, chemotherapy failed to improve survival in refractory disease, regardless of whether immunotherapy maintenance was administered.
Biological Explanations
Several biological mechanisms may explain why sequential treatment appeared superior. Radiotherapy can initially induce lymphocyte depletion, particularly when large radiation fields and definitive doses are used. Delivering immunotherapy after completion of radiotherapy may allow partial immune recovery while simultaneously taking advantage of increased tumor antigen presentation generated by radiation-induced cell death.
By contrast, concurrent treatment may expose activated immune cells to radiation-related toxicity during the most vulnerable period of immune activation.
Clinical Implications
The study offers important practical lessons for clinicians treating advanced NSCLC. First, sequential immunoradiotherapy appears to be associated with better outcomes than concurrent treatment, particularly when definitive radiotherapy is administered. Second, continuation of immunotherapy after radiotherapy in refractory disease may provide benefit for selected patients, although prospective validation is still required.
Third, chemotherapy continues to play an important role in newly diagnosed advanced disease but may contribute little in later treatment settings. Most importantly, the results emphasize that the optimal integration of radiotherapy and immunotherapy is highly context dependent. Disease stage, treatment intent, radiation dose, prior therapies, and patient fitness all appear to influence outcomes.
Conclusion
The OCEANUS study provides some of the strongest real-world evidence to date regarding the optimal integration of radiotherapy and immunotherapy in advanced NSCLC. Sequential immunoradiotherapy was associated with superior survival compared with concurrent treatment, particularly among patients receiving definitive radiotherapy. In refractory disease, immunotherapy maintenance after radiotherapy demonstrated a promising, though not statistically significant, survival signal.
Although the retrospective nature of the study prevents definitive treatment recommendations, these findings support the growing concept that treatment sequencing matters. As prospective trials continue to investigate immunoradiotherapy combinations, OCEANUS offers valuable insight into how radiotherapy, immunotherapy, and chemotherapy may be most effectively combined to improve outcomes for patients with advanced NSCLC.
